A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer

European Journal of Cancer

Volumn 51, Issue 16, 2015, Pages 2321-2329

  Giaccone, G ^a   Bazhenova, L A ^b   Nemunaitis, J ^c   Tan, M ^d   Juhasz E ^e   Ramlau, R ^f   Van Den Heuvel, M M ^g   Lal, R ^h   Kloecker, G H ⁱ   Eaton, K D ^j   Chu, Q ^k   Dunlop, D J ^l   Jain, M ^m   Garon, E B ⁿ   Davis, C S ^o   Carrier, E ^p   Moses, S C ^p   Shawler, D L ^p   Fakhrai, H ^p  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Mary Crowley Cancer Research Centers   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^f POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^g ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF LOUISVILLE   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k CROSS CANCER INSTITUTE   (Canada)

^l GLASGOW ROYAL INFIRMARY   (United Kingdom)

^m Noble Hospital   (India)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o CSD Biostatistics   (United States)

^p NovaRx Corporation   (United States)

more..

Author keywords

Cancer gene therapy; Cancer immunotherapy; Cancer vaccine; Non small cell lung cancer; TGF

Indexed keywords

BELAGENPUMATUCEL L; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; CANCER VACCINE;

ADENOSQUAMOUS CARCINOMA; ADULT; ARTHRALGIA; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE REACTION; LIMB PAIN; LUNG ADENOCARCINOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NON SMALL CELL LUNG CANCER; NONCARDIAC CHEST PAIN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL TIME; SYSTEMIC THERAPY; UNDIFFERENTIATED CARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; IMMUNOLOGY; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; TIME; TREATMENT OUTCOME;

ADULT; AGED; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84943665476     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.07.035     Document Type: Article

References (38)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 1 2014 9 29
2. M. Malvezzi, P. Bertuccio, F. Levi, V.C. La, and E. Negri European cancer mortality predictions for the year 2013 Ann Oncol 24 3 2013 792 800
3. National Comprehensive Cancer Network. NCCN guidelines non-small cell lung cancer, version 2.2013. NCCN Guidelines; 2013 [Accessed 2013].
4. M.A. Socinski, M.J. Schell, A. Peterman, and et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer J Clin Oncol 20 5 2002 1335 1343
5. Y.Y. Soon, M.R. Stockler, L.M. Askie, and M.J. Boyer Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials J Clin Oncol 27 20 2009 3277 3283
6. P. Goldstraw, J. Crowley, K. Chansky, and et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours J Thorac Oncol 2 8 2007 706 714
7. T. Ciuleanu, T. Brodowicz, C. Zielinski, and et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 9699 2009 1432 1440
8. F. Cappuzzo, T. Ciuleanu, L. Stelmakh, and et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 6 2010 521 529
9. J. Nemunaitis, R.O. Dillman, P.O. Schwarzenberger, and et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer J Clin Oncol 24 29 2006 4721 4730
10. J. Nemunaitis, M. Nemunaitis, N. Senzer, and et al. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients Cancer Gene Ther 2009
11. L.E. Raez, P.A. Cassileth, J.J. Schlesselman, and et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer J Clin Oncol 22 14 2004 2800 2807
12. J. Nemunaitis, D. Sterman, D. Jablons, and et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer J Natl Cancer Inst 96 4 2004 326 331
13. C. Butts, N. Murray, A. Maksymiuk, and et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer J Clin Oncol 23 27 2005 6674 6681
14. I. Bolonaki, A. Kotsakis, E. Papadimitraki, and et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide J Clin Oncol 25 19 2007 2727 2734
15. V.E. Neninger, A. de la Torre, R.M. Osorio, and et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer J Clin Oncol 26 9 2008 1452 1458
16. Y. Oka, A. Tsuboi, T. Taguchi, and et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression Proc Natl Acad Sci U S A 101 38 2004 13885 13890
17. M. Barve, J. Bender, N. Senzer, and et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer J Clin Oncol 26 27 2008 4418 4425
18. E.A. Hirschowitz, T. Foody, R. Kryscio, L. Dickson, J. Sturgill, and J. Yannelli Autologous dendritic cell vaccines for non-small-cell lung cancer J Clin Oncol 22 14 2004 2808 2815
19. H. Fakhrai, J.C. Mantil, L. Liu, and et al. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma Cancer Gene Ther 13 12 2006 1052 1060
20. L. Sobin, and C. Wittekind TNM Classification of Malignant Tumours 6th ed. 2002 Wiley-Liss New York
21. S.J. Pocock, and R. Simon Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 31 1 1975 103 115
22. D.J. Stewart Update on the role of topotecan in the treatment of non-small cell lung cancer Oncologist 9 Suppl 6 2004 43 52
23. C. Butts, M.A. Socinski, P.L. Mitchell, and et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial Lancet Oncol 15 1 2014 59 68
24. S.R. Gameiro, J.A. Caballero, J.P. Higgins, D. Apelian, and J.W. Hodge Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses Cancer Immunol Immunother 60 9 2011 1227 1242
25. S.R. Gameiro, J.A. Caballero, and J.W. Hodge Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing Cancer Biother Radiopharm 27 1 2012 23 35
26. J. Papay, Z. Sapi, G. Egri, and et al. Platinum-based chemotherapy in lung cancer affects the expression of certain biomarkers including ERCC1 Pathol Oncol Res 15 3 2009 445 450
27. L. Zitvogel, O. Kepp, L. Senovilla, L. Menger, N. Chaput, and G. Kroemer Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway Clin Cancer Res 16 12 2010 3100 3104
28. L.A. Emens Chemoimmunotherapy Cancer J 16 4 2010 295 303
29. S. Bretti, A. Berruti, G. Gorzegno, and et al. Multicenter Phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients Lung Cancer 14 2-3 1996 353 360
30. V. Gebbia, D. Galetta, V. Lorusso, and et al. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale) Lung Cancer 61 3 2008 369 377
31. X. Wu, Q.M. Feng, Y. Wang, J. Shi, H.L. Ge, and W. Di The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy Cancer Immunol Immunother 59 2 2010 279 291
32. X. Huang, Y.T. Chen, H.Z. Song, G.C. Huang, and L.B. Chen Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells World J Gastroenterol 17 25 2011 3002 3011
33. M.J. McCoy, R.A. Lake, R.G. van der Most, I.M. Dick, and A.K. Nowak Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies Br J Cancer 107 7 2012 1107 1115
34. L. Wu, Z. Yun, T. Tagawa, K. Rey-McIntyre, M. Anraku, and P.M. de Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model J Thorac Oncol 6 9 2011 1578 1586
35. G. Multhoff, F. Rodel, A.G. Pockley, and U.S. Gaipl Frontiers research topic: radiation-induced effects and the immune system Front Oncol 3 2013 55
36. E.A. Reits, J.W. Hodge, C.A. Herberts, and et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy J Exp Med 203 5 2006 1259 1271
37. M. Cao, R. Cabrera, Y. Xu, C. Liu, and D. Nelson Gamma irradiation alters the phenotype and function of CD4+CD25+ regulatory T cells Cell Biol Int 33 5 2009 565 571
38. S. Wei, M.U. Egenti, S. Teitz-Tennenbaum, W. Zou, and A.E. Chang Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice J Immunother 36 2 2013 124 132